81 results
8-K
EX-99.2
ltaiv6uo5d7ffoxisk
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
424B5
0terh65owy99xp rh6
2 Nov 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.1
xa8ye
13 Oct 23
Other Events
4:16pm
8-K
EX-10.1
ymvnkoy5na5hpxobfkjs
30 Aug 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
0frtazfu
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-10.2
81w6p
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-4.1
zsk05zadzke69ze20d
17 Apr 23
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
4:17pm
S-3ASR
cv4p4kygh460
9 Sep 22
Automatic shelf registration
4:31pm